Literature DB >> 1935934

Functional characterization of human recombinant apolipoprotein AIV produced in Escherichia coli.

N Duverger1, A Murry-Brelier, M Latta, S Reboul, G Castro, J F Mayaux, J C Fruchart, J M Taylor, A Steinmetz, P Denèfle.   

Abstract

Apolipoprotein AIV (apoAIV), a protein which is known to activate the enzyme lecithin: cholesterol acyltransferase, to bind to apoAI/AII receptor sites and also to promote cholesterol efflux from adipose cells, may play an important role in reverse cholesterol transport. In this report, the high-level production of soluble recombinant mature human apoAIV (isoform 1) in Escherichia coli is described. The recombinant protein was purified by avoiding lipid extraction or denaturation. The apoAIV preparation was analysed by its reactivity with antibodies raised against human apoAIV, SDS-gel electrophoresis, isoelectric focusing and N-terminal sequencing. The purified recombinant protein retains an extra methionine at the N-terminus. Purified recombinant and natural apoAIV proteins were indistinguishable with regard to their denaturation properties, thermo-stability or their fluorescence emission properties in the presence of various quantities of a quenching agent. Complexes of ApoAIV with L-alpha-dimyristoyl-glycerophosphocholine (Myr2GroPCho), glycerophosphocholine (GroPCho), or L-alpha-1-palmitoyl-2-oleoylglycerophosphocholine (PamOleGroPCho) prepared from plasmatic and from recombinant apoAIV proteins have similar densities as revealed by analytical centrifugation. They also share the same cofactor properties for the lecithin:cholesterol acyltransferase reaction. Recombinant apoAIV complex with Myr2GroPCho was also able to bind to the same apoAI/AII receptor sites and to promote cholesterol efflux to an equal extent from adipose cells. It is concluded that the recombinant protein is functionally identical to the plasmatic apoAIV and may therefore be very useful in helping to elucidate the physiological role of apoAIV.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1935934     DOI: 10.1111/j.1432-1033.1991.tb16294.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  A novel method for selective isotope labeling of bacterially expressed proteins.

Authors:  K M Lee; E J Androphy; J D Baleja
Journal:  J Biomol NMR       Date:  1995-01       Impact factor: 2.835

2.  In Vivo Exposures to Particulate Matter Collected from Saudi Arabia or Nickel Chloride Display Similar Dysregulation of Metabolic Syndrome Genes.

Authors:  Jason Brocato; Michelle Hernandez; Freda Laulicht; Hong Sun; Magdy Shamy; Mansour A Alghamdi; Mamdouh I Khoder; Thomas Kluz; Lung-Chi Chen; Max Costa
Journal:  J Toxicol Environ Health A       Date:  2015

3.  Apolipoprotein A-IV inhibits experimental colitis.

Authors:  Thorsten Vowinkel; Mikiji Mori; Christian F Krieglstein; Janice Russell; Fumito Saijo; Sulaiman Bharwani; Richard H Turnage; W Sean Davidson; Patrick Tso; D Neil Granger; Theodore J Kalogeris
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

4.  A three-dimensional homology model of lipid-free apolipoprotein A-IV using cross-linking and mass spectrometry.

Authors:  Matthew R Tubb; R A Gangani D Silva; Jianwen Fang; Patrick Tso; W Sean Davidson
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

5.  Comparative proteomics analysis provide novel insight into laminitis in Chinese Holstein cows.

Authors:  Shu-Wei Dong; Shi-Dong Zhang; Dong-Sheng Wang; Hui Wang; Xiao-Fei Shang; Ping Yan; Zuo-Ting Yan; Zhi-Qiang Yang
Journal:  BMC Vet Res       Date:  2015-07-23       Impact factor: 2.741

6.  Effects of elaidic acid on lipid metabolism in HepG2 cells, investigated by an integrated approach of lipidomics, transcriptomics and proteomics.

Authors:  Lone Vendel Nielsen; Toke P Krogager; Clifford Young; Carla Ferreri; Chryssostomos Chatgilialoglu; Ole Nørregaard Jensen; Jan J Enghild
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.